DSM completes acquisition of Glycom
DSM acquires world's leading supplier of Human Milk Oligosaccharides (HMO) for early life nutrition applications.
01 Apr 2020
Annual General Meeting 2020
Invitation to shareholders
2019 Integrated Annual Report
People, Planet & Profit performance
An introduction to DSM
Our Nutrition & Materials businesses
Financial results & presentations
Quick overview 2010 to-date
Why invest in DSM?
Our investor proposition
DSM share center
Share types, listings & ownership
- agm
- ar2019
- factbooks
- results center
- why invest
- share center
Purpose-led, Performance-driven
DSM is a global science-based company operating in the fields of Nutrition, Health and Sustainable Living. Our business is centered around developing innovative solutions and large innovation projects addressing Nutrition & Health, Climate & Energy and Resources & Circularity to drive above market growth.
Our story
DSM is positioned to drive continued above market organic growth and deliver further improvement in profitability, shareholder return and sustainability as we execute Strategy 2021.
Our performance
The Annual Results published on 13 February confirm DSM delivered a good financial performance for year and achieved the key milestones in the first year of it's Strategy 2021.
Shareholder information
We have recently celebrated the 30th anniversary of our privitisation and our ordinary shares being listed on the Euronext Stock Exchange in Amsterdam, the Netherlands.
- NUTRITION
- MATERIALS
Nutrition
We provide nutritional solutions for animal health and human well-being, serving the global feed, food & beverage, pharmaceutical, infant nutrition, dietary supplements and personal care industries.
Animal Nutrition & Health
2019
Sales: ↑€2,892 (2018: €2,749)
Organic Growth: ↑4%
Volume Growth: ↑2%
Price Growth: ↑2%
Human Nutrition
2019
Sales: ↑€2,046 (2018: €1,989)
Organic Growth: ↓1%
Volume Growth: ↑2%
Price Growth: ↓3%
Sales1
€6,028m
Adjusted EBITDA1
€1,250M
Adjusted EBITDA Margin1
20.7%
1) Underlying business, net of temporary vitamin effect
Materials
Advanced and high-performance materials for the electrical & electronics, automotive, packaging, consumer goods, life protection, transportation and telecom industries.
Sales
€2,746M
Adjusted EBITDA
€509M
Adjusted EBITDA Margin
18.5%
Latest financial & regulatory news
-
-
DSM - repurchase of shares (16-20 March 2020)
DSM repurchased 239,127 shares from 16 to 20 March 2020 at an average price of €89.77.
24 Mar 2020
-
DSM - repurchase of shares (9-13 March 2020)
DSM repurchased 705,494 shares from 9 to 13 March 2020 at an average price of €96.33.
17 Mar 2020
Our Investor Relations team are based in Heerlen, the Netherlands. The team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts. To that effect Investor Relations plans, prepares and organizes the written and oral communications with (potential) shareholders and financial analysts, deals with the stock exchange authorities and maintains the necessary databases, websites and brochures.
Dave Huizing
Vice President Investor Relations
+31 45 578 2864
Anna Morello
Investor Relations Manager
+31 45 578 2282
Marc Silvertand
Investor Relations Manager
+31 45 578 2348
Daniel Uribe
Investor Relations Analyst
+31 45 578 2864
Sandra Segers
Personal Assistant
+31 45 578 2864
Petra Volk
Support Officer
+31 45 578 2511
Read more
-
At a glance
Key facts and figures about DSM, our business and our people, planet & profit performance in one overview.
-
Factbooks
An introduction for investors and analysts to DSM, our Nutrition, Materials and Innovation Center clusters and our businesses.
-
Strategy & financial targets
DSM has set two ambitious targets for profit growth and cash generation to drive value creation for the period 2019-2021.